Literature DB >> 17709205

Relationship of the Ubiquilin 1 gene with Alzheimer's and Parkinson's disease and cognitive function.

Alejandro Arias-Vásquez1, Lonneke de Lau, Luba Pardo, Fan Liu, Bing-Jian Feng, Aida Bertoli-Avella, Aaron Isaacs, Yurii Aulchenko, Albert Hofman, Ben Oostra, Monique Breteler, Cornelia van Duijn.   

Abstract

Ubiquilin 1 (UBQLN1) is involved in the ubiquitination machinery, which has been implicated in Alzheimer's disease (AD) as well as Parkinson's disease (PD). A polymorphism in the gene encoding for UBQLN1 has been previously associated with a higher risk of AD. We studied the role of the SNP rs12344615 on the UBQLN 1 gene in AD, PD and cognitive function in a population-based study, the Rotterdam Study, and a family-based study embedded in the genetic research in isolated population (GRIP) program. The Rotterdam Study includes 549 patients with AD and 157 patients with PD. The GRIP program includes a series of 123 patients with AD and a study of 1049 persons who are characterized for cognitive function. Data were analysed using logistic and multiple regression analysis. We found no significant difference in risk of AD or PD by the UBQLN1 SNP rs12344615 in our overall and stratified analyses in the Rotterdam Study. In our family-based study, we did not find evidence for linkage of AD to the region including the UBQLN1 gene. In the family-based study we also failed to detect an effect of this polymorphism on cognitive function. Our results suggest that it is unlikely that the SNP rs12344615 of the UBQLN1 gene is related to the onset of AD, PD or cognitive function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709205     DOI: 10.1016/j.neulet.2007.07.015

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability.

Authors:  Antonella Caccamo; Smita Majumder; Janice J Deng; Yidong Bai; Fiona B Thornton; Salvatore Oddo
Journal:  J Biol Chem       Date:  2009-08-03       Impact factor: 5.157

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

3.  Cold-Inducible Protein RBM3 Protects UV Irradiation-Induced Apoptosis in Neuroblastoma Cells by Affecting p38 and JNK Pathways and Bcl2 Family Proteins.

Authors:  Rui-Juan Zhuang; Jian Ma; Xiang Shi; Fei Ju; Shuang-Ping Ma; Lei Wang; Bin-Feng Cheng; Yan-Wen Ma; Mian Wang; Tong Li; Zhi-Wei Feng; Hai-Jie Yang
Journal:  J Mol Neurosci       Date:  2017-08-22       Impact factor: 3.444

4.  Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein.

Authors:  Emily S Stieren; Amina El Ayadi; Yao Xiao; Efraín Siller; Megan L Landsverk; Andres F Oberhauser; José M Barral; Darren Boehning
Journal:  J Biol Chem       Date:  2011-08-18       Impact factor: 5.157

5.  The ubiquilin gene family: evolutionary patterns and functional insights.

Authors:  Ignacio Marín
Journal:  BMC Evol Biol       Date:  2014-03-28       Impact factor: 3.260

6.  Meta-analysis of Ubiquilin1 gene polymorphism and Alzheimer's disease risk.

Authors:  Tianpeng Zhang; Yingying Jia
Journal:  Med Sci Monit       Date:  2014-11-12

7.  Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?

Authors:  Kurt A Jellinger; Amos D Korczyn
Journal:  BMC Med       Date:  2018-03-06       Impact factor: 8.775

8.  Ubiquilin-1 and protein quality control in Alzheimer disease.

Authors:  Amina El Ayadi; Emily S Stieren; José M Barral; Darren Boehning
Journal:  Prion       Date:  2013-01-29       Impact factor: 3.931

9.  Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells.

Authors:  P P Shah; W W Lockwood; K Saurabh; Z Kurlawala; S P Shannon; S Waigel; W Zacharias; L J Beverly
Journal:  Oncogene       Date:  2014-04-21       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.